The EU is asking Australia to extend drug company monopolies. This could mean Australians wait longer for access to cheaper, generic medicines.
Academic rigour, journalistic flair
Articles on PBS
Displaying 1 - 20 of 57 articles
Without credible news and information, a healthy democracy is not possible.
There are more than 30 different types of contraceptive pills. But brand names such as Microgynon, Levlen, Yaz and Brenda give little indication of the ingredients, dose or who should use them.
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
It's exciting to think we're on the brink of a genomic revolution in health care. But just because new technology becomes available, it doesn't mean it should automatically be publicly funded.
Some argue the current system of subsidising drugs in Australia needs changing to accommodate new cancer therapies. But two recent drug listings show the current system is working perfectly well.
Have you ever wondered why some drugs are so cheap, and others so expensive? Here's why.
How, why and when do people lie – and what happens as a result?
Australia has been subsidising drugs to cure hepatitis C since March 2016. Unlike in many other countries, these are available to everyone with the disease and are much cheaper for our government.
Cyntoia Brown was just 16 years old when she shot and killed a man in 2004. Under Tennessee law, she won't be eligible for parole until she is 67 years old. Is such a harsh sentence constitutional?
The fund is nothing more than a rebadging exercise in the hope people might think it is a new policy. And it's being used to airbrush public hospitals out of the Medicare picture.
An independent expert provides his pick of the most notable drugs added to the PBS on May 1, 2017.
When the Corporation for Public Broadcasting was founded 50 years ago, it was supposed to reflect the nation's disparate voices.
As the Trump administration settles into office, regulators and lawmakers have big plans for shifting the country's media landscape, with potentially profound effects on the public.
A Grattan Institute report released today, Cutting a better drug deal, calls for a major shake-up of pharmacies and pharmaceutical pricing.
Australia is spending more than A$500 million a year too much for pharmaceuticals because of a little known loophole that allows drug companies to overcharge the government.
Health policy was an important factor in the election outcome, but one of the most important issues in the health sector – the impact of out-of-pocket costs – was mostly ignored.
With the presidential debates being derided as evidence we live in a “post-fact" political world, why aren't the moderators “truth vigilantes”?
If Australia’s new prime minister wishes to lead a successful 21st-century government, he must tackle the rise in chronic disease and use data to constantly improve the system.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Job Board
Where experts find jobs
-
Research Fellow In Geomatic Engineering
-
Commissioning Editor
-
Grants Advisor (Health And Medical)
-
Lecturer
-
Editor and General Manager
Top contributors
-
Stephen Duckett is a Friend of The Conversation.Director, Health Program, Grattan Institute
-
Professor of Health Economics, University of Melbourne
-
ARC Future Fellow, Australian National University
-
Professor of Health Economics, University of Technology Sydney
-
Professor of Journalism, Media and Communication, Queensland University of Technology
-
Professor of Health Economics, University of Adelaide
-
Dean, University of Wollongong
-
Senior Lecturer in Public Health, La Trobe University
-
Nial Wheate is a Friend of The Conversation.
Associate Professor | Program Director, Undergraduate Pharmacy, University of Sydney
-
Senior Research Fellow, University of Technology Sydney
-
Research Fellow, University of Adelaide
-
Professor, Kirby Institute, UNSW
-
Adjunct Professor, Murdoch University
-
Professor of Health Economics and Director, Centre for Health Economics Research and Evaluation, University of Technology Sydney
-
Professor; Head, School of Clinical Sciences, Queensland University of Technology
